Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
November 22, 2024 16:45 ET
|
Ocean Biomedical, Inc.
PROVIDENCE, Rhode Island, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on November 18, 2024, it received a notice from The Nasdaq Stock Market LLC...
Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers
October 03, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Company to Host Cancer R&D Update on October 19, 2023 to Share Latest Details of Multipronged Cancer Program Based on Pioneering Anti-CHI3L1 Discoveries Providence, RI, Oct. 03, 2023 (GLOBE...
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Malaria Vaccine Patent Granted in Brazil, the 25th Patent Allowance for Programs in Infectious Disease, Cancer and Fibrosis
June 08, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Patent for breakthrough approach to disrupting the malaria parasite’s life cycle adds to a growing global patent portfolio, with 25 patents issued and an additional 38 patents pending. ...